Medical Oncology Department, University Hospital, Clermont-Ferrand, France.
EA(UR)7453 CHELTER - Clermont Auvergne University, Clermont-Ferrand, France.
Mol Cancer Ther. 2024 Mar 4;23(3):272-284. doi: 10.1158/1535-7163.MCT-23-0310.
In solid tumors, three main complementary approaches of adoptive T-cell therapies were successively developed: tumor-infiltrating lymphocytes, chimeric antigen receptor engineered T cells, and high-affinity T-cell receptor engineered T cells. In this review, we summarized rational and main results of these three adoptive T-cell therapies in solid tumors field and gave an overview of encouraging data and their limits. Then, we listed the major remaining challenges (including tumor antigen loss, on-target/off-tumor effect, tumor access difficulties and general/local immunosubversion) and their lines of research. Finally, we gave insight into the ongoing trials in solid tumor.
在实体瘤中，过继性 T 细胞疗法有三种主要的互补方法：肿瘤浸润淋巴细胞、嵌合抗原受体工程 T 细胞和高亲和力 T 细胞受体工程 T 细胞。在这篇综述中，我们总结了这三种过继性 T 细胞疗法在实体瘤领域的合理依据和主要结果，并概述了令人鼓舞的数据及其局限性。然后，我们列出了主要的剩余挑战（包括肿瘤抗原丢失、靶内/靶外效应、肿瘤浸润困难和全身/局部免疫抑制）及其研究方向。最后，我们深入探讨了实体瘤的正在进行的试验。
